Hannah Bradley
Family · la Mesa, CANPI 1033865654
Payments from drug & device makers
Across 212 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$773
- UCB, Inc.$759
- AbbVie$728
- Axsome Therapeutics, Inc.$304
- Otsuka America Pharmaceutical, Inc.$289
- Teva Pharmaceuticals USA, Inc.$268
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,930100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $773 |
| UCB, Inc. | 34 | $759 |
| AbbVie | 33 | $728 |
| Axsome Therapeutics, Inc. | 5 | $304 |
| Otsuka America Pharmaceutical, Inc. | 13 | $289 |
| Teva Pharmaceuticals USA, Inc. | 11 | $268 |
| Neurelis, Inc. | 19 | $251 |
| GSK | 2 | $244 |
| Bayer | 5 | $197 |
| Amgen | 5 | $189 |
| Johnson & Johnson | 5 | $172 |
| Sanofi | 2 | $167 |
| Indivior Inc. | 8 | $166 |
| Novo Nordisk | 3 | $155 |
| Braeburn Inc. | 2 | $134 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $129 |
| Neurocrine Biosciences, Inc. | 5 | $118 |
| Lilly USA, LLC | 6 | $101 |
| Soleno Therapeutics, Inc. | 4 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $79 |
| Exact Sciences | 3 | $78 |
| Lundbeck LLC | 4 | $76 |
| Shield Therapeutics Inc | 2 | $67 |
| Acadia Pharmaceuticals Inc | 2 | $43 |
| Boehringer Ingelheim | 2 | $41 |
| Abiomed | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Novartis | 2 | $39 |
| Viiv Healthcare Company | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Eisai Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Vivus LLC | 1 | $16 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,930 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $3,918 |
| Fluvoxamine Maleate | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Other family in la Mesa
- Chun Chowla Mesa$30K
- Joy Gaola Mesa$29K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.